Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice

Richard A. Miller, David E. Harrison, C. M. Astle, Joseph A. Baur, Angela Rodriguez Boyd, Rafael De Cabo, Elizabeth Fernandez, Kevin Flurkey, Martin A. Javors, James F. Nelson, Carlos J. Orihuela, Scott Pletcher, Zelton Dave Sharp, David Sinclair, Joseph W. Starnes, J. Erby Wilkinson, Nancy L. Nadon, Randy Strong

Research output: Contribution to journalArticlepeer-review

735 Scopus citations


Rapamycin was administered in food to genetically heterogeneous mice from the age of 9 months and produced significant increases in life span, including maximum life span, at each of three test sites. Median survival was extended by an average of 10% in males and 18% in females. Rapamycin attenuated age-associated decline in spontaneous activity in males but not in females. Causes of death were similar in control and rapamycin-treated mice. Resveratrol (at 300 and 1200 ppm food) and simvastatin (12 and 120 ppm) did not have significant effects on survival in male or female mice. Further evaluation of rapamycin's effects on mice is likely to help delineate the role of the mammalian target of rapamycin complexes in the regulation of aging rate and age-dependent diseases and may help to guide a search for drugs that retard some or all of the diseases of aging.

Original languageEnglish (US)
Pages (from-to)191-201
Number of pages11
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume66 A
Issue number2
StatePublished - Feb 2011


  • Life span
  • Rapamycin
  • Resveratrol
  • TOR

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice'. Together they form a unique fingerprint.

Cite this